Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The National Breast Cancer Coalition is active in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio includes 1 pending office action. This single active matter is the primary focus of the applicant's current prosecution activities.
The prosecution is handled by 1 distinct examiner and 1 distinct art unit. This indicates that the subject matter of the filings is contained within a specific technical classification. For a practitioner, this concentration means that the prosecution strategy does not need to account for the varying practices of different art units.
JOHANSEN, PETER N. is identified as the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Since the total number of pending office actions is 1, this examiner is the sole official reviewing the active application. The practitioner should tailor their approach to the specific history and preferences of this examiner.
Having 1 distinct examiner and 1 distinct art unit provides a streamlined path for patent prosecution. The practitioner can focus entirely on the 1 pending office action, ensuring a consistent and targeted response to the examiner's requirements. This simplicity is beneficial for managing the applicant's intellectual property interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012432 | Breast Cancer Vaccine | JOHANSEN, PETER N. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012432 | Breast Cancer Vaccine | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18012432 | Breast Cancer Vaccine | JOHANSEN, PETER N. | 1644 | §102§103 | Final Rejection | — | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Breast Cancer Coalition has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Peter N. Johansen has the most, with 1 of National Breast Cancer Coalition's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
